Inhibrx Biosciences Revenue

Inhibrx Biosciences had revenue of $1.30M in the twelve months ending March 31, 2026. In the year 2025, Inhibrx Biosciences had annual revenue of $1.30M with 550.00% growth.

Revenue (ttm)

$1.30M

Revenue Growth

+550.00%

P/S Ratio

1,075.62

Revenue / Employee

$11,818

Employees

110

Market Cap

1.40B

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.30M	1.10M	550.00%
Dec 31, 2024	200.00K	-1.60M	-88.89%
Dec 31, 2023	1.80M	-392.00K	-17.88%
Dec 31, 2022	2.19M	-5.04M	-69.69%
Dec 31, 2021	7.23M	-5.66M	-43.89%
Dec 31, 2020	12.89M	-323.00K	-2.44%
Dec 31, 2019	13.21M	4.62M	53.71%
Dec 31, 2018	8.60M	204.00K	2.43%
Dec 31, 2017	8.39M	1.72M	25.86%
Dec 31, 2016	6.67M	-	-

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Novavax	596.34M
Maravai LifeSciences Holdings	204.73M
Immatics	43.00M
Maze Therapeutics	20.00M
Zenas BioPharma	10.00M

Revenue Rankings

INBX News

10 days ago - Inhibrx announces FDA acceptance of BLA for ozekibart - TheFly
10 days ago - Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma - PRNewsWire
5 weeks ago - Inhibrx price target raised to $325 from $300 at Stifel - TheFly
6 weeks ago - Inhibrx Reports First Quarter 2026 Financial Results - PRNewsWire
6 weeks ago - Inhibrx Biosciences Quarterly report: Q1 2026 - Filings
6 weeks ago - Inhibrx’s INBRX-106 shows potential benefit in HNSCC - TheFly
6 weeks ago - Inhibrx Biosciences Transcript: Study update - Transcripts
6 weeks ago - Inhibrx Biosciences Press release: Study update - Filings

More News